Isoprenaline potency(-logEC50) in the absence or presence of β2-adrenoceptor agonists on the isolated human bronchus
Drug concentration | Subjects n | -logEC50 |
PSS | 6 | 7.48±0.08 |
PSS + indacaterol | ||
10−7 M | 6 | 7.20±0.16 |
3×10−7 M | 6 | 7.81±0.15 |
PSS | 5 | 7.48±0.07 |
PSS + formoterol | ||
10−9 M | 5 | 7.59±0.16 |
3×10−9 M | 5 | 7.05±0.23 |
PSS | 6 | 7.49±0.16 |
PSS + salmeterol | ||
10−7 M | 6 | 5.58±0.35* |
3×10−7 M | 6 | 5.24±0.44* |
Data are expressed as mean±sem. PSS: physiological salt solution. *: p<0.05 versus control.